Dr. Marianne Stanford, PhD
Vice President, Research & Development IMV Inc.
Adjunct Assistant Professor, Microbiology and Immunology, Dalhousie
Member, Vaccine Discovery Group, CCfV
immunotherapy, T cell biology, translational cancer research
Research at IMV Inc. focuses on using our platform technology, DPX, to focus the immune system to treat cancer. IMV is developing a pipeline of novel therapeutic and preventive approaches for cancer and other serious diseases. Our proprietary platform provides a solution for product candidates with the potential to produce more rapid, robust and sustained immune responses. Our lead product, DPX-Survivac is in clinical development, inducing T cell responses to the tumor target survivin. In addition to being a widely recognized tumor-associated antigen (TAA), survivin also plays an important role in the dysregulated cell apoptosis and metastasis that are the hallmarks of cancer. We also actively explore immunotherapy combinations, including those with checkpoint inhibitors.